The estimated Net Worth of Scott Gunther is at least $3.8 million dollars as of 2 August 2024. Mr. Gunther owns over 666 units of Catalent stock worth over $2,363,435 and over the last 7 years he sold CTLT stock worth over $1,439,766. In addition, he makes $0 as Senior Vice President - Quality & Regulatory Affairs at Catalent.
Scott has made over 14 trades of the Catalent stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 666 units of CTLT stock worth $39,660 on 2 August 2024.
The largest trade he's ever made was exercising 7,347 units of Catalent stock on 2 October 2020 worth over $264,639. On average, Scott trades about 749 units every 52 days since 2017. As of 2 August 2024 he still owns at least 39,635 units of Catalent stock.
You can see the complete history of Mr. Gunther stock trades at the bottom of the page.
Scott Gunther is Senior Vice President - Quality & Regulatory Affairs of the Company. Mr. Gunther joined us in 2012 as Vice President, Quality and most recently oversaw the quality function for the United States sites in our Drug Delivery Solutions business unit. Previously, he concurrently served as an interim Vice President of Product Development for our Drug Delivery Solutions business unit. Prior to joining us, Mr. Gunther spent 22 years with Bristol-Myers-Squibb (“Bristol”) in various roles of increasing responsibility. In his last role at Bristol, he held the position of Executive Director Quality Operations Americas, where he was responsible for quality operations at its manufacturing sites in the U.S., Puerto Rico, and Latin America. Mr. Gunther holds a B.S. degree from the State University of New York College at Buffalo and an M.B.A. from Canisius College.
Scott Gunther is 52, he's been the Senior Vice President - Quality & Regulatory Affairs of Catalent since 2017. There are 18 older and 8 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Scott's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius et Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: